

7th European CAR T-cell Meeting

Abstract and Clinical Case Submission Guidelines

The abstract submission guidelines of the 7th European CAR T-cell Meeting are intended to provide clear instructions before submitting an abstract. **You are kindly requested to carefully read the guidelines stated below.**

EHA/EBMT and the Scientific Program Committee (SPC) of the meeting maintain the right to reject any abstract that does not meet the below requirements.

Table of Contents

Key Dates.....	2
Deadlines of Submission	2
Terms and Conditions.....	2
Submission Guidelines.....	3
Abstract and Clinical Case Topics	3
Submission Specifications	4
Review, Selection, and Publication	4
Applicable Law and Jurisdiction	5

Key Dates

July 1, 2024	Abstract/clinical case submission opens
October 31, 2024 (23:59 CET)	Abstract/clinical case submission closes
November 20, 2024	Notification of allocation
December 1, 2024 (23:59 CET)	Deadline to withdraw abstracts/clinical case (if applicable)
January 1, 2025	Late-breaker abstract/clinical case submission opens
January 12, 2025 (23:59 CET)	Late-breaker abstract/clinical case submission closes
January 20, 2025	Notification of late-breaker allocation
January 24, 2025 (23:59 CET)	Deadline to withdraw late-breaker abstracts/clinical case (if applicable)

Deadlines of Submission

There are **two deadlines** for abstract submission of the 7th European CAR T-cell Meeting, which are **October 31, 2024 (23:59 CET)** and **January 12, 2025 (23:59 CET)**. Submissions received after January 12, 2025 (23:59 CET) will not be considered.

- **Regular abstract/clinical case submission**
 - o Submission duration: July 1, 2024 - **October 31, 2024 (23:59 CET)**
 - o Authors will be informed about the allocation by November 20, 2024
- **Late-breaker abstract/clinical case submission**
 - o Submission duration: January 1, 2025 - **January 12, 2025 (23:59 CET)**
 - o Authors will be informed about the allocation by January 20, 2025

Terms and Conditions

1. The SPC encourages the submission of original scientific material unpublished at the time of the abstract/clinical cases submission deadline(s):
 - a. Abstracts/clinical cases submitted to regional or national hematology meetings can be submitted to this Scientific Meeting for inclusion in the program;
 - b. Abstracts/clinical cases submitted to large international meetings which are organized in the same period as this EHA/EBMT Scientific Meeting (January – March 2025) are allowed to be submitted to the meeting.
 - c. Abstracts/clinical cases submitted to other large international meetings may also be submitted providing a clear indication about significant novel or updated information included in the appropriate abstract/clinical case submission field.
2. Authors of submitted abstracts/clinical cases shall be the sole and exclusive owner of the abstract/clinical case and all associated intellectual property rights. By submitting the abstract/clinical case to this Scientific Meeting, the author grants EHA/EBMT the right to use and (commercially) reprint the abstract/clinical case in relation to this Scientific Meeting. Authors of submitted abstracts/clinical cases understand and agree that EHA/EBMT will not pay compensation for this license.
3. Authors of submitted abstracts/clinical cases guarantee that the abstract/clinical case (and all associated intellectual property rights) is free of any third-party rights to the fullest extent permitted by law, including but not limited to, the inventor's rights of remuneration and any other ancillary rights.

4. By submitting an abstract/clinical case, the submitting author confirms that they have approval from all the co-authors to submit and use the data in the abstract.
5. Submitted abstracts/clinical case reports are considered embargoed from the time of submission. The embargo will be lifted at the time of presentation.
6. Please do not submit the same study in multiple abstracts/clinical cases. Abstracts/clinical cases that appear as more than one version of a single study will be rejected.
7. Similarly, abstracts/clinical cases or (close) copies, may not be submitted under more than one topic.

Submission Guidelines

The submitted abstracts and cases should fully adhere to the guidelines below:

1. Abstracts/clinical cases should be submitted in clear (American) English to allow the reviewers to focus on the scientific content of the abstract/clinical case. Non-English-speaking authors are encouraged to have their abstract/clinical case checked for grammar and spelling.
2. The SPC assumes all presenting authors have proficiency in English and, thus are able to present and respond to questions.
3. In clinical studies, please state whether informed consent was obtained from patients.
4. The title and text may not contain trade names. The SPC reserves the right to replace trade names in accepted abstracts/clinical cases.
5. If off-label use of drugs was involved, please state this clearly.
6. Withdrawal policy:

If authors wish to withdraw their abstracts/clinical cases from presentation or publication, they are requested to send a letter via e-mail to the EHA Executive Office (scientificmeetings@ehaweb.org) by December 1, 2024 (23:59 CET) or January 24, 2025 (23:59 CET). Consequently, the abstract/clinical case will not be presented nor published.

- Regular abstract/clinical case submission:
Withdrawal letter (if applicable) should be sent to EHA Executive Office by **December 1, 2024 (23:59 CET)**
- Late-breaker abstract/clinical case submission:
Withdrawal letter (if applicable) should be sent to EHA Executive Office by **January 24, 2025 (23:59 CET)**

Abstract and Clinical Case Topics

Please select the most appropriate topic during the abstract and case submission:

1. Clinical case on lymphoma
2. Clinical case on adult/pediatric acute lymphoblastic leukemia
3. Clinical case on multiple myeloma
4. Clinical case on solid tumors
5. Clinical case on autoimmune diseases
6. Clinical case on management of toxicity (incl. side effects)

7. CAR-based Cellular Therapy - Preclinical: Innovative T cell engineering, CAR designs and optimization of CAR T cell function
8. CAR-based Cellular Therapy - Preclinical: CAR T cell manufacturing methodologies
9. CAR-based Cellular Therapy - Preclinical: Novel in vivo and in vitro models to functionally evaluate CAR T cells
10. CAR-based Cellular Therapy - Preclinical: Mechanistic studies of CAR T efficacy and toxicities and tumor resistance
11. CAR-based Cellular Therapy - Clinical: Clinical investigations into therapeutic applications of CAR-T cell in oncology and other fields, adult/pediatric indications
12. CAR-based Cellular Therapy - Clinical: Challenges of CAR-based cellular therapy (improving effectiveness, CAR-T cell persistence and reducing toxicity of the therapy)
13. CAR-based Cellular Therapy - Clinical: Diagnosis and treatment of toxicities (early and late)
14. CAR-based Cellular Therapy - Clinical: Biomarkers
15. Quality of Life
16. Access to CAR T

Submission Specifications

- Title count: max. 300 characters incl. space.
- Character limit: 3500 characters (incl. spaces, punctuation, and headers in the template).
- Please use the following subheadings: Background / Aims / Methods / Results / Summary - Conclusion
- Images have to be submitted as JPEG, tif, or gif files:
 - Due to limited space, only a simple graph/image can be submitted.
 - Images and graphs should reproduce well in black and white.
 - Image file should not exceed 500KB.
- Authors: There is no limit to the number of authors.
- References are obligatory when submitting an abstract or clinical case

Review, Selection, and Publication

1. All submitted abstracts/clinical cases will be reviewed by members of the Scientific Program Committee of the 7th European CAR T-cell Meeting.
2. Abstracts/clinical cases may be selected for
 - a. Oral presentation
 - b. Poster presentation
 - c. Rejection
3. Only the submitting author will receive a confirmation letter of acceptance for oral presentation, poster presentation, or a notice of rejection, by email by **November 20, 2024**, or **January 20, 2025**, according to the abstract/clinical case submission time. It is the submitting authors' responsibility to inform the presenting authors (if applicable) of the submission outcome and guidelines.

4. Authors of abstracts/clinical cases selected for an oral presentation will be informed about the date of the session and presentation guidelines will be provided.
5. Oral/poster presenters will need to register to the 7th European CAR T-cell Meeting by themselves after receiving the notification in order to present in the meeting. Oral/poster presenting authors of accepted cases will be allowed to register with the Early Bird registration discount fee, for which the details will be shared in the acceptance letter. All other authors wishing to attend the meeting should complete their registration before December 1, 2024 (23:59 CET) to take advantage of the Early Bird registration discount fee.
6. Presenting authors of abstracts/clinical cases selected for an oral presentation will be informed about the date of the oral session and will receive guidelines for their presentation.
7. Presenting authors of abstracts/clinical cases selected for a poster presentation will be informed about the date of the poster session and will receive guidelines for their presentation.
8. All accepted abstracts/clinical cases will be published in the digital abstract book for meeting attendees. Note that after publication, the abstracts/clinical cases cannot be modified.

Applicable Law and Jurisdiction

The above Terms and conditions are governed by the laws of the Netherlands. Any dispute related to these terms and conditions and the use or publication of the abstract shall be exclusively submitted to the District Court in The Hague, The Netherlands.